Alternative splicing of HER2: a novel mediator of EGFR TKI resistance

被引：1

作者：

Yochum, Zachary A. ^{[1
,2
]}

Villaruz, Liza C. ^{[1
]}

机构：

[1] UPMC Hillman Canc Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA

[2] Univ Pittsburgh, Sch Med, Med Scientist Training Program, Pittsburgh, PA USA

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2020年 / 9卷 / 04期

关键词：

CELL LUNG-CANCER; PHASE-III; BREAST-CANCER; OPEN-LABEL; 1ST-LINE; AMPLIFICATION; OSIMERTINIB; MUTATION;

D O I：

10.21037/tlcr-20-618

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1606 / 1612

页数：7

共 50 条

[21] The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, Jennifer L.
Hung, Mien-Chie
CANCER AND METASTASIS REVIEWS, 2016, 35 (04) : 575 - 588
[22] Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2
Dao, Vinh
Heestand, Gregory
CURRENT PROBLEMS IN CANCER, 2023, 47 (04)
[23] Novel dihydropyrimidines as promising EGFR & HER2 inhibitors: Insights from experimental and computational studies
Faizan, Syed
Wali, Adil Farooq
Talath, Sirajunisa
Rehman, Muneeb U.
Sivamani, Yuvaraj
Nilugal, Kiran C.
Shivangere, Narendra Babu
Attia, Sabry M.
Nadeem, Ahmed
Elayaperumal, Sumitha
Kumar, B. R. Prashantha
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 275
[24] Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance
Yin, Li
Wang, Zhao-Yi
STEROIDS, 2016, 111 : 95 - 99
[25] Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance
Morrison, Gladys
Fu, Xiaoyong
Shea, Martin
Nanda, Sarmistha
Giuliano, Mario
Wang, Tao
Klinowska, Teresa
Osborne, C. Kent
Rimawi, Mothaffar F.
Schiff, Rachel
BREAST CANCER RESEARCH AND TREATMENT, 2014, 144 (02) : 263 - 272
[26] Effects of the EGFR/HER2 kinase inhibitor gw572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance
Zhou, H
Kim, YS
Peletier, A
McCall, W
Earp, HS
Sartor, CI
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (02): : 344 - 352
[27] HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
Venetis, Konstantinos
Crimini, Edoardo
Sajjadi, Elham
Corti, Chiara
Guerini-Rocco, Elena
Viale, Giuseppe
Curigliano, Giuseppe
Criscitiello, Carmen
Fusco, Nicola
FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
[28] Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Koga, Takamasa
Kobayashi, Yoshihisa
Tomizawa, Kenji
Suda, Kenichi
Kosaka, Takayuki
Sesumi, Yuichi
Fujino, Toshio
Nishino, Masaya
Ohara, Shuta
Chiba, Masato
Shimoji, Masaki
Takemoto, Toshiki
Suzuki, Makoto
Janne, Pasi A.
Mitsudomi, Tetsuya
LUNG CANCER, 2018, 126 : 72 - 79
[29] KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer
Herreros-Villanueva, Marta
Rodrigo, Maximiliano
Claver, Manuel
Muniz, Pilar
Lastra, Enrique
Garcia-Giron, Carlos
Jesus Coma del Corral, Maria
MOLECULAR BIOLOGY REPORTS, 2011, 38 (02) : 1315 - 1320
[30] HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Xu, Xiaowei
De Angelis, Carmine
Burke, Kathleen A.
Nardone, Agostina
Hu, Huizhong
Qin, Lanfang
Veeraraghavan, Jamunarani
Sethunath, Vidyalakshmi
Heiser, Laura M.
Wang, Nicholas
Ng, Charlotte K. Y.
Chen, Edward S.
Renwick, Alexander
Wang, Tao
Nanda, Sarmistha
Shea, Martin
Mitchell, Tamika
Rajendran, Mahitha
Waters, Ian
Zabransky, Daniel J.
Scott, Kenneth L.
Gutierrez, Carolina
Nagi, Chandandeep
Geyer, Felipe C.
Chamness, Gary C.
Park, Ben H.
Shaw, Chad A.
Hilsenbeck, Susan G.
Rimawi, Mothaffar F.
Gray, Joe W.
Weigelt, Britta
Reis-Filho, Jorge S.
Osborne, C. Kent
Schiff, Rachel
CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5123 - 5134

← 1 2 3 4 5 →